Corvus Pharmaceuticals, Inc. (CRVS)

In our clinical immunology review sessions, the focus remains locked on the biomarker and immunologic data for soquelitinib presented at the Society for Investigative Dermatology. While the Phase 2 atopic dermatitis and Phase 3 PTCL trials are actively progressing on schedule, the mechanistic profile targeting ITK requires careful evaluation of safety and efficacy readouts as the late 2026 Phase 3 interim approaches.

On our trading desk, CRVS reads as a classic binary-wait setup. Following the January follow-on offering and subsequent shelf filing, the company successfully secured a cash runway extending into the second quarter of 2028 ($215.2 million at mid-year). However, with RandD expenses doubling year-over-year to $16.0 million in Q2 and expanding net losses, market participants are weighing this financial cushion against a summer catalyst void ahead of the late 2026 trial milestones.

Watching the technical and social sentiment data, CRVS has experienced wide cross-source divergence, registering a hold signal with moderate buzz. From a risk management standpoint, the invalidation triggers are clear: a daily close below the reclaimed 50-day moving average or the $12.50 zone signals that post-readout distribution has resumed, compounding the single-asset, pre-revenue risks inherent in its pipeline.